

MAMMAPRINT® RISK GROUP

Low Risk


Your care team has ordered the MammaPrint® and Blueprint® tests for your tumor. These tests help to better understand the biology of your tumor, providing important information to create the most personalized and informed treatment recommendation for you.



MAMMAPRINT+BLUEPRINT

Illuminating Tumor Biology

Low Risk



Treatment Options

CHEMOTHERAPY

Studies have shown that tumors that fall in the Low Risk range of the MammaPrint Index have a low likelihood of recurring within five years of diagnosis. They also show a minimal benefit when treated with chemotherapy.¹ Talk to your healthcare provider—avoiding chemotherapy may spare you from unnecessary treatment and side effects.

HORMONAL THERAPY

For most hormone-positive tumors, the standard treatment includes taking hormone therapy for five years.² However some Low Risk tumors may still return beyond five years after diagnosis referred to as a “late recurrence.” For MammaPrint Low Risk tumors, studies show that taking hormonal therapy for up to 10 years may help lower the risk of a late recurrence.^{3,4} Talk to your healthcare provider—extending the duration of hormonal therapy may be a beneficial option.

MammaPrint and Blueprint are two tests that work together to provide your care team with valuable insights into your tumor. These tests should be considered alongside other clinical and pathological information in partnership with your medical team. Please consult your test results for more detailed information and your care team when making decisions about your treatment.

Scan here to
continue learning
about MammaPrint
and Blueprint



MKT-204-V1

1. Cardoso F, van't Veer LJ, Bogaerts J, et al. J Clin Oncol. 2021
2. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2024.
3. Rastogi P et al. J Clin Oncol. 2024;00:1-9.
4. van 't Veer LJ, et al. JAMA. November 2024

